Stock Screener App

Frei -

Installieren

9.69

0.92% -0.09

Kazia Therapeutics Limited Adr (KZIA)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten

Kazia Therapeutics Limited (KZIA) stock price, news, quote and history - Yahoo Finance Australia

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders - Macau Business

New rare-epilepsy trial unlocks milestone cash for Kazia (NASDAQ: KZIA) - Stock Titan

Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq - The Globe and Mail

Kazia Therapeutics (NASDAQ: KZIA) shifts ADSs to JPMorgan - Stock Titan

Kazia Therapeutics Limited Announces Change of Sole Depositary for Its American Depositary Receipt - marketscreener.com

Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research

Kazia Therapeutics LimitedADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com

Kazia Therapeutics (NASDAQ: KZIA) Shows 52% Tumor Reduction in Preclinical Colorectal Cancer Model - Kalkine Media

Paxalisib shrinks tumors in models as Kazia (NASDAQ: KZIA) lines up Phase 2 cancer trials - Stock Titan

BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com Australia

Kazia Therapeutics Expands Trial in HR+/HER2- Cancer | KZIA Stock News - Stock Titan

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - The Manila Times

Kazia Therapeutics (NASDAQ: KZIA) unveils new investor site - Stock Titan

Kazia Therapeutics stock falls on $40M public offering By Investing.com - Investing.com UK

Kazia Therapeutics prices $40 million public offering By Investing.com - Investing.com UK

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering - The Globe and Mail

Kazia Therapeutics Limited Announces Proposed Public Offering - The Manila Times

Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake - Stock Titan

Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap - Stock Titan

Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS - Stock Titan

Kazia Therapeutics (KZIA) Holds Near $13.95 as Biotech ADR Consolidates Between Key LevelsParabolic SAR - vinanet.vn

Kazia files patent for breast cancer treatment strategy By Investing.com - Investing.com Nigeria

Kazia Therapeutics (NASDAQ: KZIA) files patent backed by TNBC data - Stock Titan

KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey

Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan

KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan

Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan

Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan

Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan

Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan

BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria

BTIG initiates Kazia Therapeutics stock with buy on cancer drug - Investing.com

Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView

Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan

ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum AcceleratesHot Stock Picks - DonanımHaber

KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill

Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan

Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail

Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan

KZIAKazia Therapeutics Limited ADR Options - Finviz

Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan

Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan

Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan

Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan

Kazia expands paxalisib trial enrollment to 36 patients in TNBC - Investing.com

KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill

Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan

KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative

KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan

How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Insider Monkey

INSM

$116.56

4.04%

RPRX

$58.02

0.51%

ROIV

$36.05

0.18%

ALNY

$252.56

1.11%

ONC

$362.73

0.78%

RVMD

$207.59

3.73%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters